Tejas Patil gives his non-small-cell lung cancer highlights for patients positive for HER2 or EGFR mutations including the DESTINY-Lung01 and ECOG-ACRIN 5162 studies (10:29).
08-06-2020 | ASCO 2020 | Conference coverage | Video
08-06-2020 | ASCO 2020 | Conference coverage | Video
Tejas Patil gives his non-small-cell lung cancer highlights for patients positive for HER2 or EGFR mutations including the DESTINY-Lung01 and ECOG-ACRIN 5162 studies (10:29).